Acceleron Pharma, Inc.

Acceleron Pharma, Inc.

Acceleron Pharma, Inc.

Overview
Date Founded

2003

Headquarters

128 SIDNEY STREET, CAMBRIDGE, MA, 02139

Type of Company

Public

Employees (Worldwide)

251 - 500

Industries

Biotechnology
Industrial Machinery & Manufacturing
Hospitals & Patient Services
Pharmaceuticals
Medical Support Services

Company Description

At Acceleron, we aim to transform the lives of people suffering from cancer and orphan diseases by discovering and developing innovative therapies. Acceleron scientists have world-leading expertise in developing medicines that regulate the transforming growth factor beta (TGF-ß) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, bone, and blood vessels. Based on this expertise, we have built a robust pipeline of biologic therapies targeted to key mechanisms underlying blood diseases and cancer. Since our founding in 2004, Acceleron has brought four distinct, internally-discovered, developed and manufactured products into clinical trials, and has established collaborations with leading biopharmaceutical companies and research institutions to bring these products to the patients who need them.

Contact Data
Trying to get in touch with decision makers at Acceleron Pharma, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

President & Chief Executive Officer

Chief Financial Officer

Senior Vice President, General Counsel

Chief Scientific Officer

Chief Human Resources Officer

Executive Vice President, Research & Development

Senior Vice President, Regulatory & Quality

Senior Vice President, Corporate Affairs & Investor Relations

Senior Vice President, Global Strategic Marketing

Senior Vice President, Technical Operations

Board of Directors

Former Chief Medical Officer & Head-Global Development at Bayer Pharma AG

President & Chief Executive Officer at Acceleron Pharma, Inc.

Co-Founder at Genetics Institute LLC

Senior Vice President, Finance, Global Controller & Principal Accounting Officer at Merck & Co., Inc.

Director & Secretary at ArQule, Inc.

Treasurer, Director & Senior Vice President at Acceleron Pharma, Inc.

Paths to Acceleron Pharma, Inc.
Potential Connections via
Relationship Science
You
Acceleron Pharma, Inc.
Owners & Shareholders
Details Hidden

AVCAP aims to achieve attractive returns with moderate risk. The firm invests primarily in the equity, debt and associated derivatives of companies operating in the life sciences sector and related industries with a focus on publicly traded, and late-stage private biotechnology companies.

Details Hidden

FCM seeks investments across asset classes and around the world through a process of bottom-up fundamental research and analysis emphasizing capital preservation. Their investment strategies include Credit Investments, Long/Short Equity, Merger Arbitrage, Risk Arbitrage, Real Estate Investments and Direct Investments. Investment ideas compete for capital based on in-depth, critical assessment of specific risks and rewards. Risk is monitored and managed through rigorous and thorough analysis of each investment and, at the portfolio level, through risk management analytics and overlay and tail-risk hedging.

Details Hidden

BAMCO principally manages long-only investment strategies for capital appreciation with production of income incidental to that objective. Each portfolio manager’s ability to choose appropriate investments for an account has a significant impact on their ability to achieve an account’s investment objective. The firm’s investment professionals are focused on fundamental analyses of businesses. Their primary objective is to understand the key drivers of growth and profitability of each company in which they invest. They analyze the following financial information: income statement, cash flow statement, balance sheet, turnover and ROE metrics, unit economics, and other company-specific data. This information is filtered through their valuation models, which they use to extrapolate long-term trends. They have meetings with the management which is a critical element of the firm’s research process.

Recent Transactions
Details Hidden

Merck & Co., Inc., Merck Sharp & Dohme Corp. purchase Acceleron Pharma, Inc.

Details Hidden

Acceleron Pharma, Inc. issued . USD Common Stock

Details Hidden

Acceleron Pharma, Inc. issued USD Common Stock

Insider Transactions
Details Hidden
Details Hidden
Transaction Advisors
Underwriter

Advised onAcceleron Pharma, Inc. issued . USD Common Stock

Escrow Agent

Advised onAcceleron Pharma, Inc. issued . USD Common Stock

Underwriter

Advised onAcceleron Pharma, Inc. issued USD Common Stock

Professional

Advised onAcceleron Pharma, Inc. issued . USD Common Stock

Underwriter

Advised onAcceleron Pharma, Inc. issued USD Common Stock

Managing Director, BioPharma

Advised onAcceleron Pharma, Inc. issued . USD Common Stock

Advisors & Consultants
Advisor

Executive Vice President & Chief Medical Officer at Deciphera Pharmaceuticals, Inc.

Clients

Bristol-Myers Squibb Company Our company has a strong legacy of innovation that began in New York in 1858 when Edward R. Squibb, M.D., founded a pharmaceutical company in Brooklyn, and in 1887 when two friends, William McLaren Bristol and John Ripley Myers purchased a struggling drug manufacturing firm in Clinton. Together, they laid the foundation for our company today — a global BioPharma leader that continues this legacy of innovation.

Monsanto Co. engages in the provision of agricultural products to farmers. It provides other seed companies with genetic material and biotechnology traits for their seed brands. The company was founded by John F. Queeny in 1901 and is headquartered in St. Louis, MO.

Key Stats and Financials As of
Market Capitalization
$10.6B
Total Enterprise Value
Earnings Per Share
Investors
Details Hidden

QVT Financial is a global multi-strategy hedge fund manager that invests in biotech and healthcare, energy and shipping, financials and structured finance, opportunistic and litigation, and technology.

Details Hidden

Flagship Pioneering seeks investment opportunities in companies located globally. The firm focuses on companies operating in the fields of therapeutics, life science tools & diagnostics, and bioenergy or cleantech. It provides financing for seed, early, and later-stage capital requirements. It acts as a lead investor. It also makes co-investments.

Details Hidden

Sutter Hill Ventures invests in companies located in the US. The firm targets companies operating in the fields of networking & computer technology, business & financial services, healthcare, software, consumer and investment partners sectors. They provide financing for early stage capital requirements.

Suppliers
The Salk Institute for Biological Studies Biotechnology | La Jolla, California

The Salk Institute for Biological Studies is an independent, non-profit, scientific research institute located in La Jolla, California. It was founded in 1960 by Jonas Salk, the developer of the polio vaccine; among the founding consultants were Jacob Bronowski and Francis Crick. Building did not start until spring of 1962. The institute consistently ranks among the top institutions in the US in terms of research output and quality in the life sciences

Fulcrum Therapeutics, Inc. Biotechnology | Cambridge, MA

Fulcrum Therapeutics, Inc. is a clinical stage biopharmaceutical company. The firm develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. Its product candidate includes Losmapimod and FTX-HbF. The company was founded by Michael R. Green, Danny Reinberg, Rudolf Jaenisch, Jeannie T. Lee, and Bradley E. Bernstein on August 18, 2015 and is headquartered in Cambridge, MA.

Competitors
Johnson & Johnson Pharmaceuticals - New Brunswick, New Jersey

Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government. Johnson & Johnson is headquartered in New Brunswick, New Jersey, the consumer division being located in Skillman, New Jersey. The corporation includes some 250 subsidiary companies with operations in 60 countries and products sold in over 175 countries. Johnson & Johnson had worldwide sales of $82.6 billion during calendar year 2020. Johnson & Johnson's brands include numerous household names of medications and first aid supplies. Among its well-known consumer products are the Band-Aid Brand line of bandages, Tylenol medications, Johnson's Baby products, Neutrogena skin and beauty products, Clean & Clear facial wash and Acuvue contact lenses. Johnson & Johnson's pharmaceutical arm is Janssen Pharmaceutica.

Agios Pharmaceuticals, Inc. Pharmaceuticals - Cambridge, Massachusetts

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.

United Therapeutics Corp. Pharmaceuticals - Silver Spring, Maryland

United Therapeutics Corp. operates as a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening diseases. The firm markets and sells commercial therapies to treat pulmonary arterial hypertension and high-risk neuroblastoma. It also involves in the research and development of new indications and delivery devices for its product and for the organ transplantation-related technologies. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Acceleron Pharma, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Acceleron Pharma, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Acceleron Pharma, Inc..